Section Arrow
APRE.NASDAQ
- Aprea Therapeutics
Quotes are at least 15-min delayed:2025/01/12 05:21 EST
Last
 3.655
-0.285 (-7.23%)
Day High 
3.78 
Prev. Close
3.94 
1-M High
Volume 
8.21K 
Bid
3.33
Ask
3.8
Day Low
3.61 
Open
3.63 
1-M Low
2.74 
Market Cap 
21.41M 
Currency USD 
P/E 0.42 
%Yield -- 
10-SMA 3.65 
20-SMA 3.46 
50-SMA 3.44 
52-W High 8.8465 
52-W Low 2.1501 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.80/-1.74
Enterprise Value
21.41M
Balance Sheet
Book Value Per Share
4.04
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CDTConduit Pharmaceuticals0.1233+0.0413+50.37%-- 
MRSNMersana Therapeutics0.72-0.58-44.62%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.2787+0.0227+8.87%-- 
ZVSAZyVersa Therapeutics1.47+0.29+24.58%0PE
SANASana Biotechnology3.66-0.64-14.88%-- 
Quotes are at least 15-min delayed:2025/01/12 05:21 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.